| Bio-Manguinhos/Fiocruz COVID-19 (mRNA) Vaccine Booster (NCT07640308) | The Immunobiological Technology Institute (Bio-Manguinhos) / Oswaldo Cruz Foundation (Fiocruz) | 2026-07-01 |
| Trial LEP-F1 + GLA-SE in Healthy Adult in Areas Endemic for Leprosy (NCT06627257) | The Immunobiological Technology Institute (Bio-Manguinhos) / Oswaldo Cruz Foundation (Fiocruz) | 2025-01-02 |
| Phase 1b/2a Trial to Evaluate LEP-F1 + GLA-SE in Healthy Adults and Leprosy Patients (NCT03947437) | The Immunobiological Technology Institute (Bio-Manguinhos) / Oswaldo Cruz Foundation (Fiocruz) | 2024-02-01 |
| Gene Sequencing as a Strategy for Identifying Genetic Factors Associated With Serious Adverse Events After Covid-19 Vaccines in Use in Brazil (NCT05630313) | The Immunobiological Technology Institute (Bio-Manguinhos) / Oswaldo Cruz Foundation (Fiocruz) | 2022-10-04 |
| Effectiveness of Vaccination Against COVID-19 in Brazil: Case-Control Study (NCT05621928) | The Immunobiological Technology Institute (Bio-Manguinhos) / Oswaldo Cruz Foundation (Fiocruz) | 2022-02-07 |
| Immunity Duration Study Eight Years After Vaccination of Children 12 to 23 Months With the Triple Viral Vaccine (Measles, Mumps and Rubella) (NCT05154097) | The Immunobiological Technology Institute (Bio-Manguinhos) / Oswaldo Cruz Foundation (Fiocruz) | 2022-01-04 |
| Study of Immunogenicity Equivalence of a Homologous Third Dose of Covid-19 (Recombinante) Vaccine (NCT05142488) | The Immunobiological Technology Institute (Bio-Manguinhos) / Oswaldo Cruz Foundation (Fiocruz) | 2021-11-09 |
| Immunogenicity Study of the Covid-19 (Recombinante) Vaccine With a 4 or 8 Week Interval Between the First Doses. (NCT05157178) | The Immunobiological Technology Institute (Bio-Manguinhos) / Oswaldo Cruz Foundation (Fiocruz) | 2021-07-20 |
| Secondary Attack Rate Measles Vaccine In Second Situation Contacts Cases Confirmed (NCT05592756) | The Immunobiological Technology Institute (Bio-Manguinhos) / Oswaldo Cruz Foundation (Fiocruz) | 2020-04-06 |
| Duration of Immunity 10 Years After a Dose-response Study With Yellow Fever Vaccine - Complementary Study (NCT04416477) | The Immunobiological Technology Institute (Bio-Manguinhos) / Oswaldo Cruz Foundation (Fiocruz) | 2019-04-08 |
| Study to Evaluate the Immunogenicity, Reatogenicity and Safety of Double Viral Vaccine (MR) for Measles and Rubella (NCT03148990) | The Immunobiological Technology Institute (Bio-Manguinhos) / Oswaldo Cruz Foundation (Fiocruz) | 2018-11-20 |
| Conjugate Vaccine Against Meningococcus C a Brazilian Project (NCT02858570) | The Immunobiological Technology Institute (Bio-Manguinhos) / Oswaldo Cruz Foundation (Fiocruz) | 2018-09-25 |
| Usability Study of a Self-test Prototype for Human Immunodeficiency Virus (HIV) Screening (NCT03979144) | The Immunobiological Technology Institute (Bio-Manguinhos) / Oswaldo Cruz Foundation (Fiocruz) | 2018-06-19 |
| Clinical Study of Immunity Duration of Yellow Fever Vaccine in Military (NCT03338231) | The Immunobiological Technology Institute (Bio-Manguinhos) / Oswaldo Cruz Foundation (Fiocruz) | 2017-03-27 |
| Investigation of Serious Adverse Events Following Vaccination Against Yellow Fever: Emphasis on Genetic Basis and Biological Markers (NCT03938597) | The Immunobiological Technology Institute (Bio-Manguinhos) / Oswaldo Cruz Foundation (Fiocruz) | 2017-01-30 |
| Efficacy and Safety Evaluation of the Intralesional Recombinant Human Epidermal Growth Factor (rhEGF) in Subjects With Diabetic Foot Ulcer. (NCT02554851) | The Immunobiological Technology Institute (Bio-Manguinhos) / Oswaldo Cruz Foundation (Fiocruz) | 2017-01-01 |
| Immunity Period After One Dose of Yellow Fever Vaccine in Adults and Children (Paraiba Study) (NCT02555072) | The Immunobiological Technology Institute (Bio-Manguinhos) / Oswaldo Cruz Foundation (Fiocruz) | 2016-07-01 |
| Pure Red Cell Aplasia in Patients With Chronic Kidney Disease and in Use of Epoetin Alfa (NCT02648126) | The Immunobiological Technology Institute (Bio-Manguinhos) / Oswaldo Cruz Foundation (Fiocruz) | 2015-11-01 |
| Study to Evaluate Safety and Imunogenicity of Double Viral Vaccine (MR) for Measles and Rubella (NCT02196285) | The Immunobiological Technology Institute (Bio-Manguinhos) / Oswaldo Cruz Foundation (Fiocruz) | 2015-09-01 |
| Validation of Rapid Tests for the Serological Diagnosis of HIV in 9 to 24 Months Old Children (NCT03984552) | The Immunobiological Technology Institute (Bio-Manguinhos) / Oswaldo Cruz Foundation (Fiocruz) | 2015-03-12 |
| Study of Immunogenicity, Reactogenicity and Safety of the Combined Measles, Mumps and Rubella Vaccine Produced by Bio-Manguinhos/Fiocruz in Children 12-15 Months of Age, Followed by Tetraviral Vaccine in Children 15-18 Months. (NCT01991899) | The Immunobiological Technology Institute (Bio-Manguinhos) / Oswaldo Cruz Foundation (Fiocruz) | 2015-02-01 |
| Safety and Immunogenicity Study in Young Adults the Meningococcal Serogroup C Vaccine Produced by Bio-Manguinhos (NCT01889836) | The Immunobiological Technology Institute (Bio-Manguinhos) / Oswaldo Cruz Foundation (Fiocruz) | 2014-05-01 |
| Immunity After Two Doses of Yellow Fever Vaccine (NCT02572518) | The Immunobiological Technology Institute (Bio-Manguinhos) / Oswaldo Cruz Foundation (Fiocruz) | 2014-05-01 |
| Comparative Study of the Immunogenicity of MMR (Measles, Mumps and Rubella) Single Dose and Multidose Presentations (NCT01777529) | The Immunobiological Technology Institute (Bio-Manguinhos) / Oswaldo Cruz Foundation (Fiocruz) | 2012-10-01 |
| BIP48 (Peginterferon Alfa 2b 48kDa) Compared With Pegasys® (Peginterferon 2a 40kDa) for Treatment of Chronic Hepatitis C (NCT01623336) | The Immunobiological Technology Institute (Bio-Manguinhos) / Oswaldo Cruz Foundation (Fiocruz) | 2012-01-01 |
| Comparative Pharmacokinetics and Pharmacodynamics of Peginterferon BIP48 and 40kDa in Healthy Volunteers (NCT01889849) | The Immunobiological Technology Institute (Bio-Manguinhos) / Oswaldo Cruz Foundation (Fiocruz) | 2010-10-01 |
| Interferon α 2b Pharmacovigilance Study (NCT01841775) | The Immunobiological Technology Institute (Bio-Manguinhos) / Oswaldo Cruz Foundation (Fiocruz) | 2009-05-01 |
| Serological Study in Children 12 to 23 Months Vaccinated With MMR (Measles, Mumps and Rubella) (NCT01874457) | The Immunobiological Technology Institute (Bio-Manguinhos) / Oswaldo Cruz Foundation (Fiocruz) | 2008-05-01 |